A new study found that more than half of double-vaccinated blood cancer patients had little protection against COVID-19.
SOAP-02 trial data released today letter NS cancer cell, 159 participants (128 of whom are cancer Patience. The second dose increased the seroconversion rate (development of antibodies against SARS-CoV-2) in patients with hematological malignancies,
NS data Emphasizes the continued vulnerability of hematological cancer patients to COVID-19. In the absence of the protection normally provided by vaccination, the authors authorize the importance of continuing public health measures to limit SARS-CoV-2 infection, and the urgency of booster programs, especially during periods of very high infection. Claim that the study shows sex.UK Delta Variant
Patients with solid cancers such as breast, urinary, and skin cancers also had a poor response to a single vaccination with a seroconversion rate of only 38%. However, unlike the corresponding blood cancers, these patients responded strongly to a second dose of vaccination given either at 3 or 12 weeks.
Previous studies have claimed that delaying the second jab of a healthy control improves the immune response that develops, but this new study shows that this is not the case for cancer patients. .. The author’s findings show that patients with solid tumors are less responsive to the first dose of the vaccine, so delaying the second dose will increase the length of time that the entire cancer patient remains very vulnerable. ..
The exam is led by a cross-organizational collaboration between King’s College London and the Francis Crick Institute with the support of Cancer Research UK. The SOAP-02 trial evaluated 159 individuals from the Guy’s and St Thomas’ NHS Foundation Trust. This included 31 controls, 72 solid tumors, and 56 hematological malignancies, showing a post-completion response to the two-dose COVID-19 Pfizer-BioNTech SARS-. CoV-2 vaccine schedule. In this study, we investigated antibody production (seroconversion) and its function (virus neutralization). The same is true for the T cell response after delaying the second dose of vaccine (12 weeks vs. 3 weeks). An assessment of the proportion of patients who achieved both seroconversion and a good T cell response was that only 36 achieved antibody and T cell responses compared to 78% of solid cancer patients and 88% of healthy controls. It highlighted the disadvantages of% blood cancer patients.
The authors of the study found that these vulnerable groups were vaccinated against people who continue to wear masks, social distance in crowded areas such as public transport, and school-age children who may be in contact. I urge you to be protected by. Blood cancer patients Or others at high risk.
Dr. Sheeba Irshad, Senior Author and Senior Clinical Lecturer at King’s College London, said: At the first dose or after both doses. Therefore, masks and other COVID-19 protection measures continue to be needed, especially for patients with hematological malignancies. It is also important that patients accept proposals for additional doses of the COVID-19 vaccine. Recommended by them as part of an ongoing primary vaccination series. ”
Professor Adrian Hay Day, lead author of King’s College London and the Francis Crick Institute, said: Society should wear masks and keep distance while scientists are investigating ways to make vaccines more effective for cancer patients. “
Professor Charles Swanton, Chief Clinician at Cancer Research UK, said: Cancer patients Despite two vaccinations, the antibody response to SARS-CoV-2 cannot be initiated. This has proven to be an important step in preventing the risk of severe infection.
“These results add to the increased evidence confirming the vulnerability of patients with hematological malignancies during a COVID pandemic despite being vaccinated.
“We must not forget these vulnerable patients as the world is beginning to return to normal. These patients will continue to take steps to protect them from infection and reduce the risk of serious illness. Needs an additional approach. Isolation approach for the foreseeable future. ”
Duncan R. McKenzie et al, Humoral and cell-mediated immunity to a second delay in SARS-CoV-2 BNT162b2 mRNA vaccination in cancer patients, cancer cell (2021). DOI: 10.1016 / j.ccell.2021.10.003
King’s College London
Quote: Https: //medicalxpress.com/news/2021-10-poor-immune-response-double-vaccinated.html Many double-vaccinated blood cancer patients obtained on October 21, 2021 ( Decreased immune response (October 21, 2021)
This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. The content is provided for informational purposes only.
Poor immune response in many double- vaccinated blood cancer patients Source link Poor immune response in many double- vaccinated blood cancer patients
The post Poor immune response in many double- vaccinated blood cancer patients appeared first on California News Times.